Physician profile
James Mcmanus
NPI 1174514053
$555.36
in general payments reported to CMS, 2019-2025
11 companies · $51.01 in 2025
The $51.01 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.04 · 2020: $117 · 2021: $97.48 · 2022: $73.68 · 2023: $90.69 · 2024: $92.62 · 2025: $51.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $216 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.48 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $103.71 | 2023-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Omeros Corporation | $89.10 | 2019-2020 | |
| Abbvie INC. | $82.21 | 2022-2025 | |
| Allergan, INC. | $82.05 | 2020-2021 | |
| Alcon Vision LLC | $69.54 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $36.97 | 2020-2022 | |
| Amgen INC. | $23.45 | 2024 | Tepezza |
| Ocular Therapeutix, INC. | $19.05 | 2024 | Dextenza |
| Bausch & Lomb Americas INC. | $17.84 | 2024 | Miebo |
| Coopervision INC. | $16.13 | 2025 | Myday Contact Lens |
| Novartis Pharmaceuticals Corporation | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcmanus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.